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A  vaccine  for  malaria  is  urgently  required.  The  RTS,S  vaccine  represents  major  progress,  but is only
partially  effective.  Development  of the  next generation  of highly  effective  vaccines  requires elucidation
of  the  protective  immune  response.  Immunity  to  malaria  is  known  to  be complex,  and  pattern-based
approaches  such  as global  gene  expression  proﬁling  are  ideal  for understanding  response  to vaccination
and  protection  against  disease.  The  availability  of  experimental  sporozoite  challenge  in humans  to testaccine
icroarray
iomarkers
ranscript
mmunity
candidate  malaria  vaccines  offers a  precious  opportunity  unavailable  for  other current  targets  of vaccine
research  such  as  HIV,  tuberculosis  and  Ebola.  However,  a limited  number  of  transcriptional  proﬁling
studies  in  the  context  of  malaria  vaccine  research  have  been  published  to  date.  This  review  outlines  the
background,  existing  studies,  limits  and opportunities  for gene  expression  studies  to  accelerate  malaria
vaccine  research.
ublis©  2015  The  Authors.  P
. Introduction
Malaria remains one of the world’s biggest killers with an
stimated 584,000 deaths attributable to Plasmodium falciparum
nfection in 2013 [1]. The spectres of emerging resistance of the
arasite to artemisinin drugs [2], and increasing resistance of
osquitoes to insecticides [3] mean a vaccine is urgently required.
here has been considerable progress towards a vaccine, most
otably the RTS,S vaccine, but this vaccine is only partially effec-
ive [4]. In order to design the next generation of vaccines it is
mperative to maximise our understanding of the mechanisms
f protective immune responses evoked by existing candidate
accines. Malaria is unusual in having the advantage of human
porozoite challenge for rapid assessment of candidate vaccines.
xploration of mechanisms of immune protection is therefore valu-
ble for vaccine research beyond malaria.Naturally acquired immunity to malaria requires repeated expo-
ure and is non-sterile, short-lived, and species-, strain- and
ariant-speciﬁc [5,6]. Protective immune responses against malaria
∗ Corresponding author at: University of Oxford, Centre for Tropical Medicine
nd Global Health, Nufﬁeld Department of Medicine Research Building, Old Road
ampus, Roosevelt Drive, Oxford OX3 7FZ, UK.
E-mail address: susie.dunachie@ndm.ox.ac.uk (S. Dunachie).
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.107
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
may  be humoral or cellular, and can be directed at the pre-
erythrocytic parasite, the blood stage merozoite, or to malarial
antigens on the surface of infected erythrocytes. The relative
importance of different immune responses to malaria measured
in exposed populations is unknown. Furthermore, many ﬁndings
have not been reproduced in separate populations. It is likely that
high level protection against malaria in humans depends on the
summed effect of multiple low level immune responses to several
antigens, with a different “protective signature” for each person
depending on their genetic background [7].
Parasite diversity represents a major obstacle to malaria vac-
cine development [8]. For example, around 60 different var genes
encode P. falciparum erythrocyte membrane protein 1 (PfEMP1)
[9], and this parasite diversity contributes to the slow speed
of acquisition of natural immunity [10]. Assessment of potential
markers of immunity is hindered by the fact that speciﬁc responses
may  be short-lived and ﬂuctuate with malaria season and degree of
parasitaemia [11]. Although used extensively as surrogate markers
of immunity to malaria for both vaccine studies and naturally
exposed populations, neither antibody levels nor IFN- secre-
tion, measured by ex vivo and cultured ELISPOT (enzyme-linked
immunospot assay) correlate with protection consistently between
studies. As malaria is an intracellular parasite, it is likely that a
protective vaccine would activate the cellular arm of the immune
response and be effective against the pre-erythrocytic liver stage
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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f the life cycle. It is highly possible that a combination of several
athways is required. P. falciparum causes the majority of deaths,
nd this parasite is the focus of most research for a malaria vaccine.
owever, Plasmodium vivax represents a serious threat to global
ealth.
Global pattern recognition approaches have great potential to
nravel the mechanisms of protection against malaria by candi-
ate malaria vaccines. Such approaches supplement traditional
echniques of antibody measurement and quantiﬁcation of speciﬁc
re-determined cellular responses. This review focuses on the use
f transcriptomics in malaria vaccine research.
. Malaria vaccines
The feasibility of a malaria vaccine is supported by two  main
ndings. Firstly, people in endemic areas accumulate considerable
rotection against clinical disease [12]. Secondly, 90% of volunteers
eceiving a repeated series of irradiated sporozoites via infected
osquitoes demonstrate sterile protection to over several months
13]. This irradiated sporozoite approach was originally considered
nly a research tool because of practical issues scaling for tropical
ettings. However there is now a focussed programme evaluating
ass production which has reported success in malaria-naïve sub-
ects using a stored preparation of irradiated sporozoites delivered
y the intravenous route [14].
Candidate vaccine regimens currently undergoing clinical tri-
ls can be viewed online in the WHO’s “rainbow tables” [15] and
n recent reviews [16,17]. Malaria vaccine strategies have typ-
cally targeted one or a few antigens from one of the distinct
ife-cycle stages. This is in contrast to naturally acquired immunity
hich is likely to involve broad spectrum immunity to a range of
ntigens across life-cycle stages [6]. Analysis of the P. falciparum
roteome revealed that the expression of key malarial antigens
s often not as stage-speciﬁc as was traditionally thought [18].
evertheless, certain antigens predominate at each stage. Increas-
ngly, research groups are combining antigens from more than one
ifecycle stage to develop “multi-stage” vaccines, although main-
aining potency in a combined antigen approach can be problematic
19,20].
Pre-erythrocytic vaccines act during the parasite’s brief journey
rom the skin to the liver, or target infected hepatocytes. The most
dvanced candidate malaria vaccine is the CSP-based subunit vac-
ine RTS,S (GlaxoSmithKline Biologicals, Rixensart, Belgium/Walter
eed Army Institute of Research). This is a protein-in-adjuvant vac-
ine, which targets the pre-erythrocytic stage circumsporozoite
rotein. A large number of clinical studies have featured in its
evelopment (reviewed in Ref. [21]), including a study comparing
he adjuvants AS01B and AS02A with saline in 102 malaria-naïve
ealthy adults in the USA [22]. This study is a rich resource for
xploring why some subjects were protected by the vaccine and
ome were not. A Phase III trial showed efﬁcacy against ﬁrst episode
f clinical malaria of 46% in children in the ﬁrst 18 months [4]
ut efﬁcacy in infants was less at 27%. Efforts continue to improve
his efﬁcacy, building on previous attempts to combine RTS,S with
ther antigens [23] or combine the RTS,S vaccine in a prime-boost
trategy [24,25].
Other pre-erythrocytic stage approaches include prime-boost
trategies to deliver the same antigen in different carriers, often
sing viral vectors, to optimise the innate immune milieu for
ntigen presentation [26]. Examples include using simian adeno-
irus ChAd63 as a viral vector with modiﬁed vaccinia virus Ankara
MVA) encoding TRAP (thrombospondin-related adhesion protein)
27,28], and a DNA prime, human serotype 5 adenovirus boost reg-
men encoding both CSP and apical membrane antigen-1 (AMA-1)
29].3 (2015) 5316–5320 5317
Blood stage vaccines are “anti-disease” vaccines that aim to
prevent invasion of blood cells after the liver stage, or prevent
the complications of disease, by targeting merozoite invasion of
erythrocytes, parasitised erythrocytes or prevent sequestration.
Finally, transmission-blocking vaccines seek to generate immunity
against sexual stages of the parasite [30,31]. However, current pub-
lished studies available for transcriptome studies in malaria vaccine
research are for pre-erythrocytic vaccines, which are the focus of
this review.
3. Controlled human malaria infection studies
The availability of a human experimental sporozoite chal-
lenge model for assessing protective efﬁcacy of candidate vaccines
provides an excellent opportunity to study immune responses fol-
lowing vaccination in relation to efﬁcacy (reviewed in Refs. [32,33].
Vaccinated volunteers and control participants undergo controlled
human malaria infection (CHMI) challenge with P. falciparum at the
peak vaccine immune response by one of three methods: via the
bites of infectious mosquitoes [34,35], by needle-based adminis-
tration of cryopreserved sporozoites [36] or by infected red blood
cells [37,38]. For the exposure to mosquito bites CHMI method,
laboratory-reared Anopheles stephensi mosquitoes are infected with
drug-sensitive 3D7 or NF54 strain P. falciparum parasites by game-
tocyte culture and feeding [39]. Each participant is then exposed
to the bites of ﬁve infected mosquitoes. Subjects are monitored
intensively by blood ﬁlm and quantitative PCR analysis, and treated
immediately on reaching a challenge endpoint. Vaccinated subjects
can be completely protected against challenge (“sterile protec-
tion”), show a delay to parasitaemia of at least 48 h compared to
unvaccinated control subjects consistent with partial protection
[40], or show no protection.
4. Immunity to malaria vaccines
There are many published studies exploring immune corre-
lates of protection by the RTS,S vaccine. However, a large gap
remains in our understanding of mechanisms of protection by pre-
erythrocytic candidate vaccines. Anti-CSP antibodies are associated
with protection, with a mathematical model predicting that a titre
of 51 units/ml would prevent 50% of infections and clinical malaria
episodes in children [41]. However, other immune mechanisms
contributing to protection are not well characterised. Natural expo-
sure does not induce strong levels of anti-CSP antibodies, and there
is no evidence of boosting of RTS,S-induced anti-CSP responses by
natural exposure [42]. A clinical study in malaria-naïve subjects
comparing the two adjuvants AS02A and AS01B with saline [43]
demonstrated signiﬁcantly higher anti-CSP titres induced by both
AS02A and AS01B adjuvants compared to saline, supporting the
adjuvant being a crucial factor for antibody induction. A number of
studies have explored T cell responses to RTS,S [43–49] with rela-
tionships described, including an independent association between
CSP-speciﬁc TNF+ CD4+ T cells and protection in Kenyan children
[44]. Models support a contribution to protection by CD4+ T cells
in malaria-naïve volunteers undergoing sporozoite challenge after
RTS,S [50]. There is evidence from murine studies that anti-CSP
speciﬁc CD8 T cells can protect against malaria [51] but RTS,S does
not appear to be a potent induced of CD8 T cells. A greater under-
standing of the role of regulatory immune responses to candidate
malaria vaccines is also required to optimise design [59]. Further
work exploring the interaction in endemic regions between RTS,S
vaccination, pre-existing immunity and post-vaccination malaria
exposure is of importance. Interestingly a recent study of the
breadth of humoral responses using protein arrays [52] was  con-
sistent with RTS,S vaccination leading to lower exposure to liver
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nd blood stage parasites. This contrasted with the hypothesis that
 partially effective RTS,S would lead to lower numbers of parasites
merging from the liver favouring a prolonged low level blood stage
hich in turn would facilitate naturally acquired blood stage immu-
ity to supplement the anti-CSP antibodies. The protein array data
upports an all-or-nothing hypothesis whereby malaria is either
revented by blocking sporozoite invasion of hepatocytes, or not.
The prime-boost approach is a good platform for induction
f CD8 T cells [53,54]. A correlation in humans between IFN--
roducing CD8+ T cells and protection against sporozoite challenge
as reported for the ChAd63-MVA regimen encoding ME  TRAP [27].
lsewhere, analysis for immune correlates of protection in the four
ubjects protected by the DNA-Ad5 regimen encoding CSP AMA-1
29] showed higher effector to central memory CD8+ T cell ratios
o AMA1 in three subjects and to CSP in one subject [55].
ranscriptional proﬁling of the vaccine response and
ntegration with outcome data from clinical challenge
tudies
There are very limited studies available of transcriptional pro-
ling in the context of malaria vaccine development. In a murine
lasmodium yoelii model, Tse et al. at Johns Hopkins University
loomberg School of Public Health characterised the gene expres-
ion of CSP-speciﬁc memory CD8+ T cells residing in the liver and
pleen after immunisation with irradiated sporozoites [56]. Differ-
nces in the expression of a number of genes involved in effector
unction, the cell cycle, cell trafﬁcking, transcription and intracellu-
ar signalling were reported. There was evidence of persistent T-cell
ctivation in the liver including upregulation of CD69 expression
nd genes from effector pathways, consistent with prolonged Plas-
odium antigen presentation. However, the transcriptional proﬁle
n the liver did not resemble the “memory signature” seen by
epeated Listeria exposure [57], or the T-cell exhaustion proﬁle
eported in chronic viral infection [58] in other murine studies. This
tudy demonstrates the unique environment of the liver for the
evelopment of immunity to malaria, and is a reminder that study-
ng transcription signature in only the peripheral blood is likely
o miss some details of protective responses. The ﬁnding that the
olecular signature for Plasmodium-exposed CD8+ T cells in the
iver is distinct from those reported for other pathogens is impor-
ant for understanding the mechanism of responses to malaria.
Vahey and colleagues at Walter Reed Army Institute of Research
erformed transcriptional proﬁling of 39 malaria-naïve human
ubjects in a study of RTS,S [59]. These subjects received either
he AS01B or the AS02A adjuvant [22]. In a subsequent sporozoite
hallenge, 13/39 had sterile protection against malaria, 11/39 had
 delay to parasitaemia and 15/39 had no protection. Gene expres-
ion studies were performed using peripheral blood mononuclear
ells (PBMC) from subjects isolated at several points in the trial.
Transitory changes in genes relating to a number of inﬂamma-
ory processes including apoptosis and protein kinase cascade were
eported 24 h after the ﬁnal vaccine. These could relate to the adju-
ant, the Hepatitis B antigen in the vaccine or the CSP epitope.
ive days after sporozoite challenge, principal component analy-
is (PCA) showed clustering of PBMC into distinct groups of those
hallenged but not vaccinated, those challenged and vaccinated,
nd the same subjects before vaccination or challenge. This demon-
trated that subjects vaccinated with RTS,S respond differently to
hallenge compared to unvaccinated subjects, as early as ﬁve days
ost challenge, although the genes and pathways associated with
hese clusters were not reported. Classiﬁcation and prediction anal-
sis at this timepoint ﬁve days after challenge predicted with 100%
ccuracy whether a subject went on to be completely, partially or
ot protected against malaria, using a classiﬁer set of 393 genes3 (2015) 5316–5320
including genes associated with the cell cycle and regulation of apo-
ptosis. This classiﬁer set was  only predictive when measured ﬁve
days after challenge, and was  unable to classify by outcome prior
to challenge (two weeks after ﬁnal vaccination). However gene
set enrichment analysis (GSEA) at this pre-challenge timepoint
found differential expression of genes in the proteasome degrada-
tion pathway in protected subjects compared to the non-protected
subjects, in particular for genes in the “immunoproteasome” sub-
group involved in processing peptides for Major Histocompatibility
Complex (MHC) Class 1 pathways.
This work is important because RTS,S is not thought to be
a potent inducer of CD8+ T cell responses, yet this study pro-
vides evidence of the pivotal role of CD8+/Class 1 pathways in
defence against malaria in RTS,S vaccinated subjects. Achieving suf-
ﬁcient power to evaluate global gene expression two weeks after
vaccination in the PBMC of humans who are not acutely unwell
is a challenge because of noise from the heterogeneous genetic
and environmental background of the subjects. Therefore, demon-
stration of differential expression here is a landmark step. The
robustness of this approach is conﬁrmed by a different study by
an independent group [60] which sought to identify a common
“vaccine transcriptomic signature” for responses to ﬁve different
vaccines (two for Neisseria meningitidis, two for inﬂuenza and one
for Yellow Fever). Of 1255 genes identiﬁed as a vaccine transcrip-
tomic signature common to at least 4/5 of the vaccine datasets,
1231 (98%) were present in the dataset from the RTS,S study by
Vahey et al. [59] when the RTS,S study was used as a test dataset.
A smaller study reported in this issue [61] evaluated response
to vaccination in sixteen subjects receiving one of two prime-
boost regimens: either RTS,S/AS02A and MVA-CS (CSP study), or
DNA-ME TRAP and MVA-ME TRAP (TRAP study). 14/16 subjects
underwent sporozoite challenge, and three subjects (two from CSP
study and one from TRAP study) were completely protected against
malaria with others showing a delay to parasitaemia. To focus on
the antigen-speciﬁc response to vaccination, PBMC stimulated with
peptides from the vaccines (either CSP or TRAP) were compared
to paired unstimulated PBMC. To examine the transcription pro-
ﬁle associated with protection against malaria, antigen-stimulated
PBMC were normalised pairwise to matched unstimulated PBMC
prior to analysis. The dominant transcriptional proﬁle seen across
the analyses was upregulation of genes found in the IFN- pathway.
GSEA analysis revealed strong antigen-speciﬁc positive enrich-
ment of genes associated with the proteasome after vaccination
with ME-TRAP, which is consistent with the ﬁndings of Vahey
and colleagues and may  reﬂect the T-cell inducing capabilities of
the prime-boost platform. Antigen-speciﬁc positive enrichment of
genes associated with IFN induction and antigen presentation mod-
ules was seen in subjects with complete protection from malaria
challenge. Antigen-speciﬁc negative enrichment of genes associ-
ated with stem cells, regulatory monocytes and myeloid modules
was seen in protected subjects. This study conﬁrms the beneﬁt of
focussing vaccine development efforts on strategies to optimise
activation of the proteasome for efﬁcient antigen presentation, and
suggests approaches that favour a bias in haemopoietic precursor
development towards lymphoid lineage may  improve efﬁcacy.
5. Limitations, opportunities and the future for
transcriptomics
Transcriptional studies in vaccine research often use small sam-
ple sizes, suffer from limited immunogenicity of the vaccines being
studied and represent a snapshot in time of gene expression. Conﬁr-
mation in new datasets is required, and exploration beyond gene
expression to demonstrate changes at the protein level is desir-
able. Further limits for these studies are the expense and expertise
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nvolved, but costs are decreasing and training in a systems-
ased analytic strategy can “democratize” the bioinformatics [62],
mproving accessibility to global multi-lingual researchers. PBMC
re frequently cryopreserved in vaccine studies where cellular
athways are of interest as a means of sampling the current
mmune activity. However the study by Tse et al. [56] is a reminder
f different expression occurring at different sites in the body, and
nimal models remain useful for allowing studies of sites inacces-
ible in human trials. The key role of neutrophils in response to
ntracellular pathogens is increasingly illuminated by transcrip-
ional studies [63,64] and many researchers prefer to examine
hole blood responses for this reason, although the development
f approaches to examine cell subsets is of great interest [65].
The lack of clearly deﬁned and consistent assays to predict
rotective immunity against malaria is a major obstacle in the
evelopment and testing of malaria vaccines. Elucidation of new
orrelates of protective immunity may  indicate new targets for vac-
ination and allow efﬁcient monitoring of population’s response to
accination. It is also an opportunity to learn more about antigen-
peciﬁc immunity in general. Studies in malaria-naïve populations
sing irradiated sporozoites conferring high rates of protection
14] provide ideal opportunities to compare molecular signatures
efore and after immunisation and relate this to challenge, whilst
rials of partially effective vaccines offer the chance to deﬁne
he pattern of difference between protected and non-protected
ubjects. Anecdotally a number of researchers in this ﬁeld have
ranscriptional proﬁling studies as part of their programme, and we
ope that the next few years will herald more published reports.
Evaluation of response to candidate malaria vaccines in endemic
opulations is desirable. There are technical, ﬁnancial and blood
olume-limit difﬁculties in studying transcriptomics in the ﬁeld,
ut the establishment of some ﬂexibility in storage conditions for
hole-blood in-tube RNA storage [66], and the development of
olid RNA collection methods for use of dried blood spots [67] offer
otential for tropical settings.
We  live in an exciting time for the deployment of
tate-of-the-art tools to reveal the secrets of immunity to complex
athogens. Future approaches to understanding the mechanisms
f protection of partially effective vaccines such as RTS,S should
nclude a range of approaches alongside transcriptomics such as
ultiplex cytometry, protein arrays [68] and mass spectrometry.
ranscriptomics is broadening our understanding of malaria
accine induced protective immunity, and deeper integration
f transcriptomics in clinical malaria vaccine trials will help to
dentify immune correlates and guide the design of future malaria
accines.
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